Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell
Department of Transplantation and Hepatic Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, 1630 Dongfang Road, Shanghai 200127, People's Republic of China. Biochemical and Biophysical Research Communications
(Impact Factor: 2.3).
06/2012; 423(4):826-31. DOI: 10.1016/j.bbrc.2012.06.048
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Systemic chemotherapy plays an important role in the treatment of patients with advanced liver cancer. However, chemoresistance to cisplatin is a major limitation of cisplatin-based chemotherapy in the clinic, and the underlying mechanism of such resistance is not fully understood. In the study, we found that miR-199a-5p levels were significantly reduced in HCC patients treated with cisplatin-based chemotherapy. Cisplatin treatment also resulted in decreased miR-199a-5p levels in human HCC cell lines. Forced expression of miR-199a-5p promoted cisplatin-induced inhibition of cell proliferation. Cisplatin treatment activated autophagy in Huh7 and HepG2 cells, which increased cell proliferation. We further demonstrated that downregulated miR-199a-5p enhanced autophagy activation by targeting autophagy-associated gene 7 (ATG7). More important, autophagy inhibition abrogated miR-199a-5p downregulation-induced cell proliferation. These data demonstrated that miR-199a-5p/autophagy signaling represents a novel pathway regulating chemoresistance, thus offering a new target for chemotherapy of HCC.
Available from: Amr Amin
- "The majority of relevant preclinical studies using numerous chemotherapeutics including vorinostat, cyclophosphamide, and imatinib have demonstrated that autophagy significantly inhibits the efficacy of several classes of anticancer agents and helps to drive the acquired resistance   . Furthermore, accumulating evidence has indicated that autophagy is involved in adaptation of cancer cells to chemotherapy  . These observations suggest that under chemotherapeutic treatments, autophagy is often activated as a cytoprotective mechanism for tumor cell to survive the effects of anticancer drugs which, in turn, may drive chemoresistance . "
[Show abstract] [Hide abstract]
ABSTRACT: Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Available from: Juan Francisco Aranda
- "One important question to address further is whether or not changes in miR-199a/b-5p endogenous levels influence endocytosis. The documented observation that in most of cancers miR-199a-5p expression is downregulated supports the idea that cancer cells can exploit this fact to ensure the intracellular trafficking necessary for growth, therefore enabling cancer progression (Ramsay et al., 2007; Xu et al., 2012). Intriguingly, miR-199a-5p overexpression inhibits tumor cell migration without affecting cellular proliferation and viability (Cheung et al., 2011; Duan et al., 2011). "
[Show abstract] [Hide abstract]
ABSTRACT: Small non-coding RNAs (microRNAs) are important regulators of gene expression that modulate many physiological processes, however their role in regulating intracellular transport remains largely unknown. Intriguingly, we found that the dynamin (DNM) genes, a GTPase family of proteins responsible for endocytosis in eukaryotic cells, encode the conserved miR-199a/b family of miRNAs within their intronic sequences. Here, we demonstrate that miR-199a/b regulates endocytic transport by controlling the expression of important mediators of endocytosis such as clathrin heavy chain (CLTC), Rab5A, low-density lipoprotein receptor (LDLR) and caveolin-1 (Cav-1). Importantly, miR-199a/b-5p overexpression markedly inhibits CLTC, Rab5A, LDLR and Cav-1 expression, thus preventing receptor-mediated endocytosis in human cell lines (Huh7 and HeLa). Of note, miR-199a-5p inhibition increases target gene expression and receptor-mediated endocytosis. Altogether, our work identifies a novel mechanism by which miRNAs regulate intracellular trafficking. In particular, we demonstrate that the DNM/miR-199a/b-5p genes act as a bifunctional locus that regulates endocytosis, thus adding an unexpected layer of complexity in the regulation of intracellular trafficking.
© 2015. Published by The Company of Biologists Ltd.
Available from: PubMed Central
- "Cisplatin treatment also results in decreased
miR-199a-5p levels in human HCC cell lines. miR-199a-5p/autophagy signaling
represents a novel pathway that regulates chemoresistance and thus offers a new
target for the cisplatin-based chemotherapy of HCC []. "
[Show abstract] [Hide abstract]
ABSTRACT: The pathogenesis of hepatocellular carcinoma (HCC) is not fully understood, which has affected the early diagnosis and treatment of HCC and the survival time of patients. MicroRNAs (miRNAs) are a class of evolutionarily conserved small, non-coding RNAs, which regulate the expression of various genes post-transcriptionally. Emerging evidence indicates that the key enzymes involved in the miRNA biosynthesis pathway and some tumor-specific miRNAs are widely deregulated or upregulated in HCC and closely associated with the occurrence and development of various cancers, including HCC. Early studies have shown that miRNAs have critical roles in HCC progression by targeting many critical protein-coding genes, thereby contributing to the promotion of cell proliferation; the avoidance of apoptosis, inducing via angiogenesis; and the activation of invasion and metastasis pathways. Experimental data indicate that discovery of increasing numbers of aberrantly expressed miRNAs has opened up a new field for investigating the molecular mechanism of HCC progression. In this review, we describe the current knowledge about the roles and validated targets of miRNAs in the above pathways that are known to be hallmarks of HCC, and we also describe the influence of genetic variations in miRNA biosynthesis and genes.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.